Medtronic plc, the global leader in medical technology, today announced it has launched the Avalus Ultra™ Bioprosthesis valve, its next-generation surgical aortic heart valve, in India. Innovating on the strong foundation of the Avalus™ platform with 10 years of clinical experience, the Avalus Ultra valve was specifically designed to offer ease of use at implant  and provides a durable circular foundation and reliable performance for future transcatheter aortic valve in surgical aortic valves (TAV-in-SAV) reinterventions to support patient lifetime management.  .

美敦力公司（Medtronic plc），全球医疗技术的领导者，今日宣布在印度推出其新一代外科主动脉心脏瓣膜——Avalus Ultra™生物假体瓣膜。基于拥有十年临床经验的Avalus™平台创新而来，Avalus Ultra瓣膜专为植入时的易用性而设计，提供耐用的圆形基础和可靠的性能，以支持未来在手术主动脉瓣中进行经导管主动脉瓣置换（TAV-in-SAV）再次干预，助力患者终身管理。

The low profile Avalus Ultra valve is designed to accommodate diverse patient anatomies. It offers a flexible sewing cuff for secure seating with minimal paravalvular leak (PVL) rates and replica sizers with simulated cuffs for precise sizing.  For valve-in-valve procedures, the platinum-iridium coil and tantalum badge enhance fluoroscopic visibility, supporting accurate placement and secure positioning within the anatomy during reinterventions.

Avalus Ultra低矮型瓣膜旨在适应多样化的患者解剖结构。它提供了灵活的缝合袖口，确保稳固就位并减少瓣周漏（PVL）率，并配有带模拟袖口的复刻型号尺，以实现精准尺寸匹配。在瓣中瓣手术中，铂铱线圈和钽标记增强了透视可见性，有助于在再次干预期间精确定位并稳固放置于解剖结构中。

For patients undergoing heart valve surgery, the Avalus Ultra valve offers excellent durability with good clinical outcomes. The AOA tissue treatment technology is used across a suite of Medtronic valves to help drive durable valve replacements, encompassing over half a million patients for over 30 years.

对于接受心脏瓣膜手术的患者，Avalus Ultra 瓣膜提供了出色的耐用性和良好的临床效果。AOA 组织处理技术应用于美敦力一系列瓣膜产品中，有助于实现持久的瓣膜置换，30多年来已涵盖超过50万名患者。

Backed by clinical studies, this innovation brings hope for a healthier future to thousands of Indian patients..

在临床研究的支持下，这一创新为成千上万的印度患者带来了更健康的未来的希望。

Commenting on the launch, Prateek Tiwari, Senior Director, Neuroscience and Specialty Therapies at Medtronic India, said '

在评论此次发布时，美敦力印度公司神经科学与专科治疗高级总监普拉蒂克·蒂瓦里表示：

The Avalus Ultra valve is designed to simplify implantation, enhance reliability, and provide clinicians with a solution that supports consistent, long-term outcomes

Avalus Ultra瓣膜旨在简化植入过程、提高可靠性，并为临床医生提供一个支持一致且长期效果的解决方案。

for their patients. Every feature reflects Medtronic’s commitment to advancing cardiac care, equipping surgeons with precise and dependable tools, and helping them deliver care that is tailored to each patient’s needs. Our aim is to support clinicians at every step of the surgical journey to deliver on our Medtronic Mission to alleviate pain, restore health, and extend life..

为了他们的患者。每个特性都反映了美敦力致力于推进心脏护理，为外科医生提供精确可靠的工具，帮助他们提供符合每位患者需求的护理。我们的目标是在手术过程的每一步支持临床医生，实现我们美敦力减轻疼痛、恢复健康、延长生命的使命。

With this launch, the company aims to provide Indian patients with a proven offering in the surgical aortic valve space with studied and proven results in the PERIGON Pivotal Trial

通过此次发布，该公司旨在为印度患者提供在手术主动脉瓣领域经过验证的产品，并在PERIGON关键试验中展示了经过研究和验证的结果。

.  The trial demonstrated stable hemodynamics and excellent durability of the Avalus valve with 99% freedom from structural valve deterioration (SVD) and severe hemodynamic dysfunction (SHD) requiring reintervention through seven years of follow-up. Supported by over 10 years of clinical experience with the Avalus valve, the Avalus Ultra device continues to demonstrate industry-leading effective orifice areas, stable low gradients, and durable performance.

该试验表明，Avalus瓣膜在七年随访期间表现出稳定的血液动力学和极佳的耐久性，99%的患者未出现结构性瓣膜恶化（SVD）和需要再次干预的严重血液动力学功能障碍（SHD）。基于超过十年的Avalus瓣膜临床经验，Avalus Ultra装置继续展现出行业领先的有效开口面积、稳定的低压差和持久的性能。

With this launch, Medtronic reinforces its commitment to equipping clinicians with reliable surgical solutions and supporting patients’ long-term cardiac health. .

通过此次发布，美敦力再次表明了其为临床医生提供可靠的手术解决方案，并支持患者长期心脏健康的承诺。

About Medtronic

美敦力公司简介

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.

大胆思考。更大胆的行动。我们是美敦力。美敦力公司总部位于爱尔兰戈尔韦，是全球领先的医疗技术公司，通过寻找并发现解决方案，勇敢地应对人类面临的最严峻健康问题。我们的使命——减轻病痛、恢复健康、延长生命——将遍布150多个国家的95,000多名充满热情的员工团结在一起。

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.

我们的技术和疗法治疗70种健康状况，包括心脏设备、手术机器人、胰岛素泵、手术工具、患者监测系统等。凭借我们丰富的知识、永无止境的好奇心和帮助所有需要帮助的人的愿望，我们提供了创新的技术，每秒、每小时、每一天都在改变两个人的生活。

Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit .

期待我们带来更多成果，因为我们正在赋能以洞察力为导向的护理、以人为本的体验，以及为我们的世界创造更好的结果。在我们所做的每一件事中，我们都在创造非凡。欲了解有关美敦力的更多信息，请访问。